CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

A Combination of Allogeneic Stem Cells Promotes Cardiac Regeneration Discharge Against Medical Advice After Percutaneous Coronary Intervention in the United States Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD Interleukin-1 Beta as a Target for Atherosclerosis Therapy: Biological Basis of CANTOS and Beyond Impact of Artificial Intelligence on Interventional Cardiology: From Decision-Making Aid to Advanced Interventional Procedure Assistance Timing and Causes of Unplanned Readmissions After Percutaneous Coronary Intervention: Insights From the Nationwide Readmission Database The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels

Clinical Case StudySeptember 18, 2019

JOURNAL:JAMA Cardiol. Article Link

Syncope After Percutaneous Coronary Intervention

Tsushima T, Sahadevan J, Intini A. Keywords: syncope; PCI; clinical case

ABSTRACT


A man in his late 50s with a history of remote coronary artery bypass grafting presented with unstable angina and underwent percutaneous coronary intervention with a drug-eluting stent. He was discharged and prescribed ticagrelor, 90 mg twice daily, in addition to his home regimen of aspirin and metoprolol tartrate. Three months later, he experienced worsening exertional dyspnea and had multiple episodes of syncope. He had no history of syncopal episodes or arrhythmias. His baseline transthoracic echocardiogram results demonstrated normal systolic function and no significant valvular disease. Ambulatory electrocardiogram (ECG) monitoring results showed 31 episodes of high-grade atrioventricular (AV) block (AVB), with ventricular pauses ranging from 3.0 to 13.0 seconds occurring during the day and at night. Among them, 4 episodes were associated with presyncope.